Status:
COMPLETED
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Lead Sponsor:
Novartis
Conditions:
Hypertension
Left Ventricular Hypertrophy
Eligibility:
All Genders
55+ years
Phase:
PHASE4
Brief Summary
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass ...
Eligibility Criteria
Inclusion
- Males or female patients ≥ 55 years of age
- LVH as confirmed by echocardiogram
- Patients with high risk hypertension, currently treated or already taking antihypertensive medication
Exclusion
- Renal artery stenosis
- Symptomatic heart failure or known ejection fraction \< 40%
- Myocardial infarction or stroke within 6 months
- Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers
- Pregnant or lactating females
- Cancer within the last 5 years
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00139555
Start Date
July 1 2004
End Date
November 1 2006
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936